A method and a system for identifying the quality of a liquid pharmaceutical product as described. The method comprises providing a liquid pharmaceutical product in a sealed container and arranging the sealed container such that the liquid pharmaceutical product forms a sample layer in a first portion of the sealed container. The method further comprises directing a light beam through the sample layer and measuring a spectrum of the sample layer. The spectrum is chosen from the group of a NIR spectrum or a Raman spectrum. The method further comprises identifying the quality of the liquid pharmaceutical product by comparing the spectrum with a reference spectrum corresponding to an expected pharmaceutical product.

A method and a system for identifying the quality of a liquid pharmaceutical product as described. The method comprises providing a liquid pharmaceutical product in a sealed container and arranging the sealed container such that the liquid pharmaceutical product forms a sample layer in a first portion of the sealed container. The method further comprises directing a light beam through the sample layer and measuring a spectrum of the sample layer. The spectrum is chosen from the group of a NIR spectrum or a Raman spectrum. The method further comprises identifying the quality of the liquid pharmaceutical product by comparing the spectrum with a reference spectrum corresponding to an expected pharmaceutical product.

The invention is a flexible and configurable inspection system for the inspection of container units that combines and integrates a holding assembly for multiple containers integrating servo-controlled rotation of the units, transport and positioning of the containers that simulate human handling, and camera stations employing automated vision inspection. The system performs horizontal inspection for particulate and any other container defect that promotes particulate to better locate within the inspection area of the cameras. Inspection sequences and product recipes combine the typical manual inspection agitation with automated inspection rotational techniques to optimize detection. The system allows for semi-automatic operation with the operator at the front of the station feeding and out-feeding material manually or fully automated with conveyance system feeding and out-feeding material from the back of the station.

The invention is a flexible and configurable inspection system for the inspection of container units that combines and integrates a holding assembly for multiple containers integrating servo-controlled rotation of the units, transport and positioning of the containers that simulate human handling, and camera stations employing automated vision inspection. The system performs horizontal inspection for particulate and any other container defect that promotes particulate to better locate within the inspection area of the cameras. Inspection sequences and product recipes combine the typical manual inspection agitation with automated inspection rotational techniques to optimize detection. The system allows for semi-automatic operation with the operator at the front of the station feeding and out-feeding material manually or fully automated with conveyance system feeding and out-feeding material from the back of the station.

The present invention relates to a method for screening an anticancer agent by causing drosophila having the characteristics of a) expression of mutant Ras85D, b) deletion or suppressed expression of a p53 gene, c) overexpression of a cyclin E gene, and d) deletion or suppressed expression of a Med gene to ingest a test substance and comparing the survival rate thereof with the survival rate of drosophila that did not ingest the test substance. The present invention also relates to a combination drug of at least two kinase inhibitors for treatment of pancreatic cancer and to kinase inhibitors for use in said combination drug.

An in vitro intestinal drug disposition device (1) comprises a donor chamber (2) for a donor solution and having a bottom end (18) and a top end (19). The device (1) also comprises a receiver chamber (3) for an absorption solution and an absorption membrane (4) arranged in between and separating the chambers (2, 3). A first side (5) of the absorption membrane (4) is to be in contact with the donor solution and a second side (6) of the absorption membrane (4) is to be in contact with the absorption solution. A ratio of an internal volume of the donor chamber (2) to an area of the first membrane side (5) is equal to or smaller than 3 ml/cm.sup.2. A cross-sectional area of the donor chamber (2) at the bottom end (18) is larger than a cross-sectional area of the donor chamber (2) at the top end (19).

An in vitro intestinal drug disposition device (1) comprises a donor chamber (2) for a donor solution and having a bottom end (18) and a top end (19). The device (1) also comprises a receiver chamber (3) for an absorption solution and an absorption membrane (4) arranged in between and separating the chambers (2, 3). A first side (5) of the absorption membrane (4) is to be in contact with the donor solution and a second side (6) of the absorption membrane (4) is to be in contact with the absorption solution. A ratio of an internal volume of the donor chamber (2) to an area of the first membrane side (5) is equal to or smaller than 3 ml/cm.sup.2. A cross-sectional area of the donor chamber (2) at the bottom end (18) is larger than a cross-sectional area of the donor chamber (2) at the top end (19).

Disclosed is a detection method for N-nitrosodimethylamine (NDMA) impurities, comprising: (1) obtaining a test solution containing a sample to be tested; and (2) detecting the test solution by means of gas chromatography-mass spectrometry to determine the content of an N-nitrosodimethylamine impurity in the sample. The method provided in the present invention has a good separating effect, a wide linear range, a high sensitivity and a good method durability, and can detect the content of N-nitrosodimethylamine (NDMA) in the sample rapidly and effectively.

Disclosed is a detection method for N-nitrosodimethylamine (NDMA) impurities, comprising: (1) obtaining a test solution containing a sample to be tested; and (2) detecting the test solution by means of gas chromatography-mass spectrometry to determine the content of an N-nitrosodimethylamine impurity in the sample. The method provided in the present invention has a good separating effect, a wide linear range, a high sensitivity and a good method durability, and can detect the content of N-nitrosodimethylamine (NDMA) in the sample rapidly and effectively.

The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions. ##STR00001##